![Pharmaceuticals & Biotechnology | Pharma & Biotech Resources show](https://d3dthqtvwic6y7.cloudfront.net/podcast-covers/000/037/269/small/pharmaceuticals-biotechnology-pharma-biotech-resources.jpg)
Summary: The proportion of clinical trials in Phase I has increased significantly in the last number of years. This coupled with a number of Phase III failures has put increased emphasis on making the right decision as early as possible. Nancy Widener, Executive Director, Clinical Science and